The availability of biosimilar products may improve access to healthcare by increasing the
number of therapeutic options available at potentially lower costs. 1 As of April 2019, 18 …

PURPOSE: Despite increasing availability of biosimilar cancer treatments, little is known
about oncologists' knowledge and concerns regarding biosimilar use in the United States …

Background: As the cost of cancer care continues to rise, biosimilars provide an important
cost-saving treatment option. Thus, understanding barriers to biosimilar uptake, including …

Biosimilarsare nonpatented biologic products that are similar to reference biologic agents in
structure, function, activity, safety, and efficacy. In 2014, investigators from the RAND …

The Patient Protection and Affordable Care Act of 2010 included the Biologics Price
Competition and Innovation Act (BPCI Act), which enables the introduction of biosimilar …

91 Background: Biosimilar agents are changing the clinical landscape in oncology. We
sought to measure oncologists' competence and knowledge of biosimilars and to address …

Challenges of Integrating Biosimilars Into Clinical Practice - PMC Back to Top Skip to main
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main …

Biosimilars will enter the US market soon, potentially lowering costs and increasing patient
access to important oncology biologics. Biosimilars are highly similar, but not identical, to …

In 2015, the United States Food and Drug Administration (FDA) approved the first biosimilar,
filgrastim-sndz, a biosimilar of the granulocyte colony-stimulating factor filgrastim. Since that …

PURPOSE: The increased number and expanded utilization of biosimilars raise important
considerations for their safe and appropriate use in oncology practice. This report provides …